SG11201804402WA - Thermostable fgf2 polypeptide, use thereof - Google Patents
Thermostable fgf2 polypeptide, use thereofInfo
- Publication number
- SG11201804402WA SG11201804402WA SG11201804402WA SG11201804402WA SG11201804402WA SG 11201804402W A SG11201804402W A SG 11201804402WA SG 11201804402W A SG11201804402W A SG 11201804402WA SG 11201804402W A SG11201804402W A SG 11201804402WA SG 11201804402W A SG11201804402W A SG 11201804402WA
- Authority
- SG
- Singapore
- Prior art keywords
- gly
- lys
- leu
- brno
- ser
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 101150019331 FGF2 gene Proteins 0.000 title 1
- YSFTYXKQUONNFY-NQXPEFQPSA-N fgf2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 title 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 abstract 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 abstract 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 abstract 1
- YNSGXDWWPCGGQS-YUMQZZPRSA-N Arg-Gly-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O YNSGXDWWPCGGQS-YUMQZZPRSA-N 0.000 abstract 1
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 abstract 1
- CGXQUULXFWRJOI-SRVKXCTJSA-N Arg-Val-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O CGXQUULXFWRJOI-SRVKXCTJSA-N 0.000 abstract 1
- VDCIPFYVCICPEC-FXQIFTODSA-N Asn-Arg-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O VDCIPFYVCICPEC-FXQIFTODSA-N 0.000 abstract 1
- NONWUQAWAANERO-BZSNNMDCSA-N Asp-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 NONWUQAWAANERO-BZSNNMDCSA-N 0.000 abstract 1
- IXPSSIBVVKSOIE-SRVKXCTJSA-N Cys-Ser-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O IXPSSIBVVKSOIE-SRVKXCTJSA-N 0.000 abstract 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 abstract 1
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 abstract 1
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 abstract 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 abstract 1
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 abstract 1
- DUAWRXXTOQOECJ-JSGCOSHPSA-N Gly-Tyr-Val Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O DUAWRXXTOQOECJ-JSGCOSHPSA-N 0.000 abstract 1
- DKJWUIYLMLUBDX-XPUUQOCRSA-N Gly-Val-Cys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O DKJWUIYLMLUBDX-XPUUQOCRSA-N 0.000 abstract 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 abstract 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 abstract 1
- QMUHTRISZMFKAY-MXAVVETBSA-N His-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N QMUHTRISZMFKAY-MXAVVETBSA-N 0.000 abstract 1
- XMAUFHMAAVTODF-STQMWFEESA-N His-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 XMAUFHMAAVTODF-STQMWFEESA-N 0.000 abstract 1
- LNJLOZYNZFGJMM-DEQVHRJGSA-N Ile-His-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N LNJLOZYNZFGJMM-DEQVHRJGSA-N 0.000 abstract 1
- UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 abstract 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 abstract 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 abstract 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 abstract 1
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 abstract 1
- LAGPXKYZCCTSGQ-JYJNAYRXSA-N Leu-Glu-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LAGPXKYZCCTSGQ-JYJNAYRXSA-N 0.000 abstract 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 abstract 1
- KQFZKDITNUEVFJ-JYJNAYRXSA-N Leu-Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=CC=C1 KQFZKDITNUEVFJ-JYJNAYRXSA-N 0.000 abstract 1
- JPNRPAJITHRXRH-BQBZGAKWSA-N Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O JPNRPAJITHRXRH-BQBZGAKWSA-N 0.000 abstract 1
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 abstract 1
- XFOAWKDQMRMCDN-ULQDDVLXSA-N Lys-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CC1=CC=CC=C1 XFOAWKDQMRMCDN-ULQDDVLXSA-N 0.000 abstract 1
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 abstract 1
- KXYLFJIQDIMURW-IHPCNDPISA-N Lys-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CCCCN)=CNC2=C1 KXYLFJIQDIMURW-IHPCNDPISA-N 0.000 abstract 1
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 abstract 1
- RFEXGCASCQGGHZ-STQMWFEESA-N Phe-Gly-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O RFEXGCASCQGGHZ-STQMWFEESA-N 0.000 abstract 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 abstract 1
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 abstract 1
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 abstract 1
- WKQNLTQSCYXKQK-VFAJRCTISA-N Trp-Lys-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WKQNLTQSCYXKQK-VFAJRCTISA-N 0.000 abstract 1
- KLQPIEVIKOQRAW-IZPVPAKOSA-N Tyr-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KLQPIEVIKOQRAW-IZPVPAKOSA-N 0.000 abstract 1
- RGJZPXFZIUUQDN-BPNCWPANSA-N Tyr-Val-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O RGJZPXFZIUUQDN-BPNCWPANSA-N 0.000 abstract 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 abstract 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 108010062796 arginyllysine Proteins 0.000 abstract 1
- 108010038633 aspartylglutamate Proteins 0.000 abstract 1
- 108010047857 aspartylglycine Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001671 embryonic stem cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 abstract 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 abstract 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 abstract 1
- 108010010147 glycylglutamine Proteins 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 108010092114 histidylphenylalanine Proteins 0.000 abstract 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract 1
- 108010034529 leucyl-lysine Proteins 0.000 abstract 1
- 108010016686 methionyl-alanyl-serine Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 abstract 1
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 102200031779 rs3204853 Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Birds (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15196802 | 2015-11-27 | ||
PCT/EP2016/073567 WO2017089016A1 (en) | 2015-11-27 | 2016-10-03 | Thermostable fgf2 polypeptide, use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804402WA true SG11201804402WA (en) | 2018-06-28 |
Family
ID=54754475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804402WA SG11201804402WA (en) | 2015-11-27 | 2016-10-03 | Thermostable fgf2 polypeptide, use thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US11746135B2 (ja) |
EP (1) | EP3380508B1 (ja) |
JP (1) | JP7131772B2 (ja) |
KR (1) | KR102650035B1 (ja) |
CN (1) | CN108779158A (ja) |
AU (1) | AU2016359722B2 (ja) |
BR (1) | BR112018010676A2 (ja) |
CA (1) | CA3006388C (ja) |
ES (1) | ES2824479T3 (ja) |
LT (1) | LT3380508T (ja) |
PL (1) | PL3380508T3 (ja) |
SG (1) | SG11201804402WA (ja) |
WO (1) | WO2017089016A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112190531B (zh) * | 2019-06-19 | 2022-11-01 | 湖北医药学院 | 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法 |
BR112022005225A2 (pt) * | 2019-09-19 | 2022-08-16 | Univ Northwestern | Meio de cultura econômico e protocolo para células-tronco pluripotentes induzidas humanas |
WO2021107473A1 (ko) | 2019-11-25 | 2021-06-03 | 한국해양과학기술원 | 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도 |
KR102428940B1 (ko) * | 2019-11-25 | 2022-08-03 | 한국해양과학기술원 | 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도 |
CZ309550B6 (cs) * | 2021-06-15 | 2023-04-05 | Enantis s.r.o | Termostabilní polypeptid na bázi FGF18 a jeho použití |
GB2616475A (en) * | 2022-03-11 | 2023-09-13 | Multus Biotechnology Ltd | Engineered fibroblast growth factor variants |
WO2024110932A1 (en) * | 2022-11-25 | 2024-05-30 | Btl Healthcare Technologies A.S. | The fgf-2 polypeptides with improved stability, the process for preparing the fgf-2 polypeptides and use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU614137B2 (en) | 1988-06-06 | 1991-08-22 | Takeda Chemical Industries Ltd. | Stabilized fgf composition and production thereof |
US5202311A (en) | 1988-08-19 | 1993-04-13 | Children's Medical Center Corporation | Stabilized fgf composition |
CA2020654A1 (en) | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Stabilized fgf composition and production thereof |
US5143829A (en) | 1990-03-29 | 1992-09-01 | California Biotechnology Inc. | High level expression of basic fibroblast growth factor having a homogeneous n-terminus |
CA2172137C (en) * | 1993-09-24 | 1999-12-14 | Andrew Peter Seddon | Surface loop structural analogues of fibroblast growth factors |
CN1252716A (zh) | 1997-02-26 | 2000-05-10 | 西布莱克斯公司 | 无前导序列蛋白输出的抑制剂 |
US7754686B2 (en) | 2000-08-31 | 2010-07-13 | Novartis Vaccines And Diagnostics, Inc. | Stabilized FGF formulations containing reducing agents |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
EP1444995A1 (en) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FGF-2 derived proteins for the preparation of biomaterials or medical devices such as stents |
US7816140B2 (en) * | 2005-06-14 | 2010-10-19 | The United States Of America As Represented By The Department Of Veterans Affairs | Composition and methods for osteogenic gene therapy |
US20070212332A1 (en) | 2005-08-11 | 2007-09-13 | Department Of Veterans Affairs | Methods for accelerating bone repair |
US8962556B2 (en) | 2006-09-28 | 2015-02-24 | Prochon Biotech Ltd. | FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof |
US7659379B1 (en) | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
EP2333074A1 (en) * | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
EP2588594B1 (en) | 2010-07-01 | 2022-11-30 | Regenerative Research Foundation | Methods for culturing undifferentiated cells using sustained release compositions |
US9169309B2 (en) | 2011-03-01 | 2015-10-27 | Humanzyme Inc. | Thermostable variants of fibroblast growth factors |
US9925270B2 (en) | 2011-11-28 | 2018-03-27 | The Regents Of The University Of California | bFGF-polymer conjugates, methods for making the same and applications thereof |
WO2013090911A1 (en) | 2011-12-16 | 2013-06-20 | Wisconsin Alumni Research Foundation | Method for supporting human pluri potent stem cell cultures comprising culturing the cells in a medium comprising thermostable fgf - 1 proteins |
US8772460B2 (en) | 2011-12-16 | 2014-07-08 | Wisconsin Alumni Research Foundation | Thermostable FGF-2 mutant having enhanced stability |
US9474785B2 (en) * | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
EP2930181B1 (en) * | 2014-04-07 | 2017-10-11 | Miltenyi Biotec GmbH | Fibroblast growth factor muteins with increased activity |
-
2016
- 2016-10-03 CN CN201680076784.3A patent/CN108779158A/zh active Pending
- 2016-10-03 LT LTEP16781318.7T patent/LT3380508T/lt unknown
- 2016-10-03 AU AU2016359722A patent/AU2016359722B2/en active Active
- 2016-10-03 BR BR112018010676-3A patent/BR112018010676A2/pt active Search and Examination
- 2016-10-03 ES ES16781318T patent/ES2824479T3/es active Active
- 2016-10-03 JP JP2018546742A patent/JP7131772B2/ja active Active
- 2016-10-03 SG SG11201804402WA patent/SG11201804402WA/en unknown
- 2016-10-03 KR KR1020187018035A patent/KR102650035B1/ko active IP Right Grant
- 2016-10-03 WO PCT/EP2016/073567 patent/WO2017089016A1/en active Application Filing
- 2016-10-03 EP EP16781318.7A patent/EP3380508B1/en active Active
- 2016-10-03 PL PL16781318T patent/PL3380508T3/pl unknown
- 2016-10-03 CA CA3006388A patent/CA3006388C/en active Active
- 2016-10-03 US US15/778,743 patent/US11746135B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108779158A (zh) | 2018-11-09 |
LT3380508T (lt) | 2020-11-10 |
CA3006388A1 (en) | 2017-06-01 |
WO2017089016A1 (en) | 2017-06-01 |
EP3380508B1 (en) | 2020-07-22 |
JP2019500414A (ja) | 2019-01-10 |
ES2824479T3 (es) | 2021-05-12 |
US11746135B2 (en) | 2023-09-05 |
AU2016359722B2 (en) | 2020-09-17 |
PL3380508T3 (pl) | 2021-07-12 |
EP3380508A1 (en) | 2018-10-03 |
CA3006388C (en) | 2023-05-09 |
JP7131772B2 (ja) | 2022-09-06 |
US20200270320A1 (en) | 2020-08-27 |
KR102650035B1 (ko) | 2024-03-20 |
KR20180080335A (ko) | 2018-07-11 |
BR112018010676A2 (pt) | 2019-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804402WA (en) | Thermostable fgf2 polypeptide, use thereof | |
SG11201806988UA (en) | Improved differentiation method | |
SG11201806398YA (en) | Optimized factor viii genes | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
SG11201811405QA (en) | Improved differentiation method | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201804162WA (en) | Compositions comprising bacterial strains | |
SG11201807022XA (en) | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors | |
SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
SG11201806542PA (en) | Anti-mica antibodies | |
SG11201407175RA (en) | Enhanced affinity t cell receptors and methods for making the same | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201807134RA (en) | Transposon system and methods of use | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201803642WA (en) | Bacteria-based protein delivery |